Notification of Interim Results
19.05.2006
LONDON, 19 May 2006 – Optos plc (LSE:OPTS) (‘Optos’ or the ‘Company’), a leading medical technology company for the design, development, manufacturing and marketing of retinal imaging devices, will be announcing its interim results for the six month period ended 31 March 2006 on Thursday 25 May 2006.
Stephane Sallmard, Chief Executive Officer, and Allan Watson, Chief Financial Officer, will host a presentation for analysts at Goldman Sachs, 133 Fleet Street, Peterborough Court, 10th Floor Auditorium from 09h30 to 11h00.
Notes to Editors
Optos is incorporated in Scotland under the Companies Act 1985 with registered number SC139953 and with its subsidiaries collectively is known as Optos plc. Founded in 1992 Optos plc is a leading medical technology company for the design, development, manufacturing and marketing of devices able to image the retina, the light-sensitive area at the back of the eye. Optos’ platform technology is the Panoramic200 Scanning Laser Ophthalmoscope device – known as the P200. In a quarter of a second the P200 device produces a high resolution image of up to 200 degrees or approximately 80 percent of the retina in a single capture. The image – branded the optomap® – provides eye care practitioners with clinically useful information that facilitates the early detection of disorders and diseases evidenced in the retina. Optos believes that its technology provides an unequalled combination of wide-field retinal imaging, speed and convenience for both practitioner and patient. Optos plc is headquartered in Dunfermline, Scotland and currently has approximately 200 employees serving more than 2,000 customers in four country markets – USA, Canada, UK and Germany. Optos plc trades on the Main Market of the London Stock Exchange under the symbol OPTS.
Enquiries
John McNeil
Director of Communications & Assistant Company Secretary
+44 (0) 1383 843 337
+44 (0) 7870 240 325